Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Non-Current Liabilities (2023 - 2025)

Kura Oncology (KURA) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $561.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 62.76% to $561.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $561.1 million, a 62.76% increase, with the full-year FY2025 number at $561.1 million, up 62.76% from a year prior.
  • Total Non-Current Liabilities was $561.1 million for Q4 2025 at Kura Oncology, up from $403.9 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $561.1 million in Q4 2025 to a low of $30.4 million in Q1 2023.
  • A 3-year average of $197.5 million and a median of $52.3 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: grew 23.87% in 2024, then surged 687.96% in 2025.
  • Kura Oncology's Total Non-Current Liabilities stood at $51.0 million in 2023, then soared by 576.5% to $344.7 million in 2024, then soared by 62.76% to $561.1 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Total Non-Current Liabilities are $561.1 million (Q4 2025), $403.9 million (Q3 2025), and $374.3 million (Q2 2025).